RECFIVED

AUG 3 1 PAID

GROUP 1800
PATENT



Docket No. <u>2016-4000US3</u>

#23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

RALPH M. STEINMAN, ET AL

Group Art Unit: 1651

Serial No

08/261,537

Examiner: Leon Lankford, Jr.

Filed

June 17, 1994

For

METHOD FOR IN VITRO PROLIFERATION OF

DENDRITIC CELL PRECURSORS AND THEIR

USE TO PRODUCE IMMUNOGENS

INFORMATION DISCLOSURE STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application.

	application and are made of record to assist the Patent and Trademark Office in its examination of this ar					
08/26/1998 01 FC:126			occords 18861537 For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:			
	2.	[]	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.			
	3.	[]	Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed			

		Docket No. <u>2016-4000US3</u>						
4.		[] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:						
	[]	37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on; or						
	[]	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or						
	[]	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.						
5.	complia date of	[] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.						
6.	complia	[X] A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):						
	[X]	A check in the amount of \$240.00 is enclosed in payment of the fee.						
	[]	Charge the fee to Deposit Account No. 13-4500. Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.						
7.	[] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:							
	a. []	one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and						
	b. []	the attached petition requesting consideration of this Information Disclosure Statement; and						
	c. []	the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.						

- 8. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
 - a. [] 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
 - b. [] 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanies by the attached Petition To withdraw Application From Issue.
 - c. [] The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.

			Docket No	2016-4000US3		
9. []	I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.					
	[]	I hereby certify that no item of information in the was cited in a communication from a foreign parto my knowledge after make reasonable inquiry §1.56(c) more than three months prior to the file	atent office in a counterpar v, was known to any individual	t foreign application or, dual designated in		
10. []	A check	c in the amount of \$130.00 is enclosed in payment	nt of the fee due under C.F.	R. §1.17(i)(1).		
	[]	Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
	[X]	The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2016-4000US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
		Re	espectfully submitted,			
		M	ORGAN & FINNEGAN, I	L.L.P.		
Dated:	Augus	st 21, 1998 By	:	MMMM / /		

Kenneth H. Somenfeld Registration No. 33,285

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

FORM: IDS.NY Rev. 05/26/98



Docket No. 2016-4005

ITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

RALPH M. STEINMAN, ET AL.

Group Art Unit: 1651

Serial No.

08/261,537

Examiner: Leon Lankford, Jr.

Filed

June 17, 1994

For

METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS

EXPRESS MAIL CERTIFICATE

Express Mail Label No. <u>EE 414511671US</u>

RECFIVED AUG 3 1 PAID

Date of Deposit August 21, 1998

GROUP 1800

I hereby certify that the following attached paper(s) and/or fee

- 1. INFORMATION DISCLOSURE STATEMENT
- 2. FORM PTO-1449
- 3. COPIES OF REFERENCES LISTED ON FORM PTO-1449 (56 references)
- 4. CHECK \$240.00
- RETURN RECEIPT POSTCARD

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

KENNETH H. SONNENFELD

(Typed or printed name of person mailing paper(s) and/or fee

Signature of person mailing paper(s) and/or fee)

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile FORM: EXP-MAIL.NY

Rev. 05/27/98